DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Obesity market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Obesity drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Obesity treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Obesity: An Overview
Obesity is recognized as a chronic or noncommunicable disease, which is a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity, or body fatness which can manifest metabolically and not just with respect to the size of the body.
As per the World Health Organization (WHO), obesity is classified on the basis of body mass index (BMI). BMI is further evaluated in terms of fat distribution via the waist–to–hip ratio and total cardiovascular risk factors. In children, a healthy weight varies according to age and sex.
Due to the psychological and social stigma associated with being overweight and obese, those affected are also vulnerable to discrimination in their personal and work lives, low self-esteem, and depression. Childhood obesity results in the same comorbidities as obesity, with premature onset or with a greater likelihood in adulthood.
Obesity results from an interaction between an individual’s genetic predisposition to weight gain and environmental influences. The severe forms and the majority of the early-onset monogenic forms of obesity have aroused from gene mutations in the leptin-melanocortin axis, particularly LEPR encoding for the leptin receptor, POMC (pro-opiomelanocortin), MC4R (melanocortin-4 receptor), NTRK2 (tropomyosin receptor kinase B receptor), and SIM1 (single-minded 1 transcription factor).
Obesity Market Key Facts
-
The total Obesity market size in the United States accounted for USD 847 million in 2021.
-
In EU5, the total Obesity market size was USD 185 million in 2021.
-
In Japan, the total market size of obesity was USD 21 million in 2021.
-
In the year 2021, the total prevalent cases of obesity in adults (>19 years) were 182.22 Million (M), and in children (5–19 years) was 7.85 million in the 7MM, which is expected to grow by 2032.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Obesity pipeline therapies. It also thoroughly assesses the Obesity market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Obesity drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Obesity Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Obesity epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Obesity epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Obesity Epidemiology, Segmented as –
-
Total prevalent cases of obesity in the 7MM for the study period 2019 to 2032
-
Total obesity patients seeking help in the 7MM for the study period 2019 to 2032
-
Total treated cases of obesity in the 7MM for the study period 2019 to 2032
Obesity Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Obesity market or expected to be launched during the study period. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Obesity drugs based on their sale and market share.
The report also covers the Obesity pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Obesity companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Obesity Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market
Obesity Therapeutics Analysis
With the increase in the prevalence of obesity cases around the globe, it has become a major health concern that warrants the development of new therapeutic options for its treatment and management. Because obesity is one of the leading causes of death worldwide, there is tremendous potential for the players engaged in the obesity treatment landscape.
Approved treatments for obesity – particularly pharmacotherapy – mostly remain underutilized. The reasons underlying the low uptake of medical therapy for obesity are complex, ranging from practical issues of insurance coverage and cost to concerns about safety and efficacy, as well as continued disease-related stigma, even among providers. The weight-loss medications that are approved by the US FDA include, CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), XENICAL (orlistat), QSYMIA (phentermine-topiramate), WEGOVY (semaglutide), and IMCIVREE (setmelanotide). As obesity is not an immediately life-threatening disease, these drugs are required to be safe. Anti-obesity drugs that have been developed so far have limited efficacies and considerable adverse effects affecting tolerability and safety.
Several major pharma and biotech companies are developing therapies for Obesity. Currently, Novo Nordisk is leading the therapeutics market with its Obesity drug candidates in the most advanced stage of clinical development.
Obesity Companies Actively Working in the Therapeutics Market Include
180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, BioRestorative Therapies, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd., Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and many others.
Emerging and Marketed Obesity Therapies Covered in the Report Include:
-
CT-868: Carmot Therapeutics
-
DD01: D&D Pharmatech
-
EMP16: Empros Pharma
-
ERX-1000: ERX Pharmaceuticals
-
RZL-012: Raziel Therapeutics
-
Semaglutide oral: Novo Nordisk
-
Tesomet: Saniona
-
Tirzepatide: Eli Lilly and Company
-
ZP 8396: Zealand Pharma
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Obesity Competitive Intelligence Analysis
4. Obesity Market Overview at a Glance
5. Obesity Disease Background and Overview
6. Obesity Patient Journey
7. Obesity Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices
9. Obesity Unmet Needs
10. Key Endpoints of Obesity Treatment
11. Obesity Marketed Therapies
12. Obesity Emerging Drugs and Latest Therapeutic Advances
13. Obesity Seven Major Market Analysis
14. Attribute Analysis
15. Obesity Market Outlook (In US, EU5, and Japan)
16. Obesity Companies Active in the Market
17. Obesity Access and Reimbursement Overview
18. KOL Views on the Obesity Market
19. Obesity Market Drivers
20. Obesity Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
DelveInsight’s specialized oncology consulting empowers the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at @ Oncology Consulting Services
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research